[{"subject":"論以保險商品比較平臺推動，普惠金融之可行性","dataClassName":null,"pubUnitName":"科技法律研究所","posterDate":null,"updateDate":null,"detailContent":"<span style=\"color:#990000;\"><span style=\"font-size:115%;\"><strong>Study on the Feasibility of Promoting Financial Inclusion by Insurance Product Comparison Platform</strong></span></span><br />\r\n<strong>作者：</strong>曾允君<br />\r\n<strong>出版年月</strong>：202109<br />\r\n<strong>關鍵詞：</strong>保險商品比較平臺；普惠金融；保險科技；資訊整合；網路保險服務；Insurance Product Comparison Platform；Financial Inclusion；InsurTech；Information Integration；Online Insurance<br />\r\n<br />\r\n<strong><span style=\"background-color:#f1c40f;\">中文摘要</span></strong><br />\r\n客觀且健全之保險商品比較平臺所具資訊整合及網路保險功能，應具有減省保險消費者取得適合保險商品之成本、促成保險市場商品資訊透明度等功能，有助於降低弱勢個人或群體接觸、瞭解及利用保險商品之障礙，促成普惠金融之落實。若得藉法令或政策安排，由具相當專業性之客觀中立第三方建置保險商品比較平臺無償提供民眾使用，並開放各保險業者得於該平臺執行網路保險服務，且適度容許第三方業者透過開放應用程式介面方式提供更多元應用服務，應更具推動及落實普惠金融之效益。<br />\r\n<br />\r\n<strong><span style=\"background-color:#f1c40f;\">英文摘要</span></strong><br />\r\nnsurance product comparison platform has the function of information integration and online insurance service, which can reduce the cost of insurance consumers to obtain suitable insurance products, increase the transparency of insurance product information, and then help reduce the barriers of vulnerable individuals or groups to contact, understand and use insurance products, and finally achieve the goal of financial inclusion. If a professional, objective and neutral third party can set up an insurance product comparison platform through appropriate laws and policies, which can be used by the public free of charge and allow various insurance companies to provide online insurance services, even further allow other third-party operators to provide more diversified application services through the open application interface, the financial supervision environment shall be more conducive to promote and implement the benefits of financial inclusion.<br />\r\n<br />\r\n<br />\r\n&nbsp;","summary":"","liaisonper":null,"liaisontel":null,"liaisonfax":null,"liaisonemail":null,"docs":[{"fileurl":"https://www.nycu.edu.tw/lawreviewlaw/ch/app/data/doc?module=nycu0040&detailNo=1528428007218221056&type=s","pdffileurl":"","odffileurl":"","expFile":"曾允君，論以保險商品比較平臺推動，普惠金融之可行性"}],"images":[],"videos":[],"audios":[],"resources":[]},{"subject":"基因編輯技術，對歐盟基因改造生物管理之挑戰","dataClassName":null,"pubUnitName":"科技法律研究所","posterDate":null,"updateDate":null,"detailContent":"<span style=\"color:#990000;\"><span style=\"font-size:115%;\"><strong>The Challenge of Gene Editing Technology for EU Genetically Modified Organisms Regulation</strong></span></span><br />\r\n<strong>作者：</strong>謝碧蓮<br />\r\n<strong>出版年月</strong>：202109<br />\r\n<strong>關鍵詞：</strong>基因編輯；新育種技術；基因改造生物；定點核酸酶；寡核苷酸定點突變；2015/2283新穎性食品規則；Gene Editing；New Breeding Technologies；Genetic Modified Organisms；Site-Directed Nuclease；Oligonucleotide-Directed Mutagenesis；Regulation (EU) 2015/2283<br />\r\n<br />\r\n<strong><span style=\"background-color:#f1c40f;\">中文摘要</span></strong><br />\r\n基因編輯技術（gene editing）是21世紀生物科技的重大進展，新育種技術即是運用基因編輯技術，精準誘發基因突變開發新品種，相較傳統的育種技術，更為快速且成本低廉，提升產量緩解糧食不足的危機，對於人類及環境永續發展帶來重大利益，然而，國際間對於基因編輯技術之管理仍未有定論，實則與基因改造生物（genetically modified organisms, GMOs）之管理策略有關，採產品導向模式的國家可能認為無須特別訂定相關管理的政策，而採製程導向模式的國家可能認為應以GMOs加以管制。對於GMOs一向採取嚴格管制的歐盟，在歐盟法院裁決利用基因編輯技術產生誘變的育種技術仍屬GMOs，雖為基因編輯技術以及其產品屬性予以定位，卻造成新興科技發展與相關產業的衝擊，引發新一波的基因技術的爭論，歐盟理事會也要求執委會提出一份關於利用基因編輯技術與傳統技術產生誘變的評估報告。未來對於基因編輯技術及其產品之合理管理政策的發展，仍值得持續關注。​​​​​​​<br />\r\n<br />\r\n<strong><span style=\"background-color:#f1c40f;\">英文摘要</span></strong><br />\r\nGene editing is a major advancement of biotechnology in the 21st century. Compared with conventional breeding technologies, gene editing technology is more effective and precise. This new breeding technology not only improves the yield and nutritional value of crops, but also offer the resolutions for food security. However, many countries are struggling with the regulatory status of this new technology; one of major concerns is related with the strategies of genetically modified organisms. Some countries, represented by the United States, regulating GM crops on a product-basis, will think that there is no necessity to establish relevant regulation or policies for genome-edited crops; others, including EU member states, adopting process-based GM crop regulations, may regard the products obtained by using gene editing technology as GMOs, and these products should need a more rigorous risk assessment throughout the process of GM crop development. Recently, the Court of Justice of the European Union ruled that the organisms obtained by using gene editing technology to generate mutations are regarded as GMOs. The ruling marked the next round of the dispute around the genetic engineering in Europe. The European Council requested the European Committee to submit an evaluation report between the new breeding technologies and conventional breeding technologies in this year. In the future, we look forward to the development of reasonable regulation for gene editing technology and its products.<br />\r\n<br />\r\n&nbsp;","summary":"","liaisonper":null,"liaisontel":null,"liaisonfax":null,"liaisonemail":null,"docs":[{"fileurl":"https://www.nycu.edu.tw/lawreviewlaw/ch/app/data/doc?module=nycu0040&detailNo=1528427800489365504&type=s","pdffileurl":"","odffileurl":"","expFile":"謝碧蓮，基因編輯技術，對歐盟基因改造生物管理之挑戰"}],"images":[],"videos":[],"audios":[],"resources":[]},{"subject":"生醫研究與資本市場之監理──以資訊揭露（解盲）為核心","dataClassName":null,"pubUnitName":"科技法律研究所","posterDate":null,"updateDate":null,"detailContent":"<span style=\"color:#990000;\"><span style=\"font-size:115%;\"><strong>Biomedical Research and Capital Market Supervision&mdash;Focus on Information Disclosure (Unblind)</strong></span></span><br />\r\n<strong>作者：</strong>李毓華<br />\r\n<strong>出版年月</strong>：202109<br />\r\n<strong>關鍵詞：</strong>解盲；重大訊息；資訊揭露；生技；解盲數據解讀；Unblind；Materially（Substantially）Information Disclosure；Biotech；Unblind Data Interpretation<br />\r\n<br />\r\n<strong><span style=\"background-color:#f1c40f;\">中文摘要</span></strong><br />\r\n生醫研究、生技產業研發週期長、研發成功率低、風險高、資金需求大，對外籌資於此領域顯得十分重要，資金取得管道通常有二：1.公部門：政府補助或投資，如行政院國家開發基金或經濟部科專補助。2.私人：民間募資。而可成為生技產業中、長期穩定資金來源者通常是資本市場，然因研發結果有其不確定性，為避免此種不確定性成為資本市場投資之阻力，可透過適時公布研發進度及成果消弭投資者之疑慮及不確定感，因適時公布研發進度及成果之目的除了是公司對股東的揭露義務外，也是吸引潛在投資者進入市場之良方。此外，為了避免公司為了籌措資金而過度誇大研發結果（如解盲結果）或故意隱匿部分資訊，造成市場上資訊接收者因資訊不對稱之情況下，做出錯誤的投資決定，因此生技公司研發成果揭露之規範十分重要。同時，生醫領域之資訊內容之複雜可能造成投資者理解上之困難，可能因而造成私人資金不進入之募資困境，因此制訂適度資訊揭露使得資訊透明度增加，並補足資訊落差。本文認為，所謂適度揭露乃符合目的性（達到資訊對稱：透明度、理解度）手段性、比例性（成本考量）之揭露機制。舉例而言，解盲數據之解讀，如何正確解讀解盲數據，切勿落入用單一結果便進行判斷，如何引導投資者正確解讀解盲數據有其重要性，如果用適當之輔助機制協助理解解盲數據，更能幫助投資者理解數據之背後含意，其方法如：允許廠商為一定「客觀」之說明，避免過度樂觀、誇大解盲數據。本文以下內容試圖討論生技產業哪些事項具有重要性而需要揭露，相關資訊（解盲數據）若需揭露時揭露之方法、密度及應權衡之相關權益（金融監管、營業秘密、投資大眾資訊獲知權等）。​​​​​​​<br />\r\n<br />\r\n<strong><span style=\"background-color:#f1c40f;\">英文摘要</span></strong><br />\r\nBiomedical research and biotechnology industry have a long R&amp;D cycle, low R&amp;D success rate, high risk, and large funding needs. It is very important to seek external funds in this field. There are two sources of funding: 1. The public sector: Government subsidies or investments, such as the National Development Fund of the Executive Yuan or the Ministry of Economic Affairs subsidies. 2. The private sector: Private fundraising. Capital market (private funding) is a medium and longterm stable source. However, due to the uncertainty of R&amp;D results, timely announcement of R&amp;D progress and results is not only the company&rsquo;s disclosure obligation to shareholders, but also a good way to attract potential investors to enter the market. To avoid the company from overly exaggerating R&amp;D results (such as unblinding) or deliberately concealing some information to obtain funds, proper and appropriate disclosure of information by a corporation is essential for the long term. Therefore, the standard of disclosure of the research and development results of biotechnology companies is important. At the same time, the complexity of the information content in the biomedical field may cause difficulties for investors to understand, which may result in the financing dilemma of private investment not being invested. Therefore, the formulation of appropriate information disclosure increases information transparency and fills up the information gap. The author believes that moderate disclosure is a disclosure method that meets the purpose (to achieve information symmetry: transparency, understanding) and proportionality (cost consideration).<br />\r\n&nbsp;","summary":"","liaisonper":null,"liaisontel":null,"liaisonfax":null,"liaisonemail":null,"docs":[{"fileurl":"https://www.nycu.edu.tw/lawreviewlaw/ch/app/data/doc?module=nycu0040&detailNo=1528427476257083392&type=s","pdffileurl":"","odffileurl":"","expFile":"李毓華，生醫研究與資本市場之監理──以資訊揭露（解盲）為核心"}],"images":[],"videos":[],"audios":[],"resources":[]},{"subject":"重審臺灣憲法法院的政治角色──以大法官釋字第261號為例","dataClassName":null,"pubUnitName":"科技法律研究所","posterDate":null,"updateDate":null,"detailContent":"<span style=\"color:#990000;\"><span style=\"font-size:115%;\"><strong>Reexamining the Role of the Constitutional Court in Taiwan&rsquo;s Democratization&mdash;Evidence from the J.Y. Interpretation No. 261</strong></span></span><br />\r\n<strong>作者：</strong>王金壽；宋昱嫺<br />\r\n<strong>出版年月</strong>：202109<br />\r\n<strong>關鍵詞：</strong>大法官；憲法法庭；261號解釋；民主化；司法政治；Justice；Constitutional Court；J.Y. Interpretation No. 261；Democratization；Judicial Politics<br />\r\n<br />\r\n<strong><span style=\"background-color:#f1c40f;\">中文摘要</span></strong><br />\r\n本文透過分析大法官釋字第261號出現的政治背景，重新檢視臺灣憲法法院在民主化過程中扮演的角色。釋字第261號長期以來被許多法律學者視為是推動臺灣民主化最重要的釋憲案。在這個釋憲案中，大法官為第一屆多年未被改選的中央民代設下了確切的退職期限，促成了國會全面改選。法律學者大多對此釋憲案有很高的評價，認為大法官展現了民主化的機能。本文挑戰這樣的觀點。我們透過分析憲法法院作成釋字第261號時的政治脈絡，論證大法官在民主化過程並非扮演民主倡議者的角色，反之，他們的角色較接近於政治潮流的旁觀者。即使沒有261號解釋文，臺灣的民主化進程並沒有太大的影響。我們同時論證261號解釋文有下列三個政治功能：第一、為當時的執政者解決一個政治上的燙手山芋；第二、解決臺灣政治上的異常質；第三、合法化政治上的大趨勢。​​​​​​​<br />\r\n<br />\r\n<strong><span style=\"background-color:#f1c40f;\">英文摘要</span></strong><br />\r\nMost Taiwan law scholars claimed that the Constitutional Court paved the way for Taiwan&rsquo;s democratization and constitutional reforms. These legal studies consider the J.Y. Interpretation No. 261 as the most critical decision in Taiwan&rsquo;s democratic transition as this decision provided the constitutional foundations for the retirement of the first-term national representatives and led to subsequent constitutional reforms. In this paper, we challenge this dominant view. We reexamine the political role of the Constitutional Court during the processes of Taiwanese democratization by citing J.Y. Interpretation No. 261 as a hard case. We argue that the Constitutional Court made little contribution to Taiwan&rsquo;s democratization. This paper shows that the role of Taiwan&rsquo;s Constitutional Court in the process of democratization has been far more complicated and far less promising than is commonly thought. We also argue that J.Y. Interpretation No. 261 provides at least three political functions for the dominant party: first, it solved a political dilemma for the political elites; second, it helped the political elites to remove the political outliners. Third, it legitimated the ruling party&rsquo;s political agenda.<br />\r\n&nbsp;","summary":"","liaisonper":null,"liaisontel":null,"liaisonfax":null,"liaisonemail":null,"docs":[{"fileurl":"https://www.nycu.edu.tw/lawreviewlaw/ch/app/data/doc?module=nycu0040&detailNo=1396850995174051840&type=s","pdffileurl":"","odffileurl":"","expFile":"重審臺灣憲法法院的政治角色──以大法官釋字第261號為例"}],"images":[],"videos":[],"audios":[],"resources":[]}]